DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Camidanlumab tesirine
Camidanlumab tesirine
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
ADC Therapeutics SA (Exact Name of Registrant As Specified in Its Charter)
Antibody–Drug Conjugates: the Last Decade
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Natural Killer Cell-Based Immunotherapy for Acute Myeloid Leukemia
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
CD25-Targeted Antibody–Drug Conjugate Depletes Regulatory T
Highlights in Hodgkin Lymphoma from the 62Nd American Society Of
Antibody–Drug Conjugates for Cancer Therapy
Stembook 2018.Pdf
Latest Advances in the Management of Classical Hodgkin Lymphoma: the Era of Novel Therapies
2018 Medicines in Development for Cancer
(INN) for Biological and Biotechnological Substances
PDF of Antibody News
2020 Medicines in Development ꟷ Cancer
Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
Advances in Therapy for Relapsed Or Refractory Hodgkin Lymphoma
2020 Medicines in Development for Children
Top View
Swiss Biotech Report 2018
Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
18Th Annual Indy Hematology Review
ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT- 301 in Patients with Relapsed Or Refractory Hodgkin Lymphoma
Vago and Gojo, Immune Escape and Immunotherapy of AML Supplementary Table 1 and 2
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri